Pharma Reviews: Citi India sees Sensex at 30000 mark by March 2017
“There have been multiple issues including USFDA concerns and generic pricing in the US, but we feel Indian pharma companies have the right ...
Read more: Citi India sees Sensex at 30000 mark by March 2017